Cullinan's CLN-978 Phase 1 Data Shows Robust B-Cell Depletion, Favorable Safety
CGEM has more than doubled off its 52-week low of $5.68 on elevated volume (2.2× avg).
Summary
Cullinan Therapeutics announced positive initial Phase 1 OUTRACE data for its drug candidate CLN-978, demonstrating robust B-cell depletion and a favorable safety profile in patients with treatment-refractory rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). The data, which will be presented at EULAR, showed that 9 of 11 patients achieved over 75% peripheral B-cell depletion at 10 mcg, with early clinical signals of improvement in both RA and SLE patients. This positive early-stage clinical data is a significant de-risking event for a biotech company, indicating potential efficacy and tolerability for a key pipeline asset. Investors will be watching for updated data presentations in June 2026 and the progression of CLN-978 into later-stage clinical trials.
At the time of this announcement, CGEM was trading at $14.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $913.9M. The 52-week trading range was $5.68 to $16.74. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.